Irritable Bowel Syndrome

Positive phase 2 results for irritable bowel syndrome treatment reported

Published in Health and Medicine Week, January 31st, 2005

Vela Pharmaceuticals Inc. (Vela), a privately held company specializing in the "re-discovery" and development of medicines related to the nervous system, including the brain-gut axis, announced positive results from its phase 2 clinical trial of dextofisopam for the treatment of irritable bowel syndrome (IBS).

Dextofisopam provided relief in both women and men with either diarrhea-predominant or alternating-type IBS. Some symptoms were relieved as early as the second day of treatment. Dextofisopam was well tolerated and did not cause constipation.

This double-blind, placebo-controlled phase 2 trial under U.S. IND enrolled 141 patients at centers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2005-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry